Adma Biologics (ADMA) Finished Goods (2017 - 2025)

Adma Biologics has reported Finished Goods for 9 years, with the latest figure at $52.1 million in Q4 2025.

• For the quarter ending Q4 2025, Finished Goods rose 8.18% year-over-year to $52.1 million; the trailing twelve-month figure through Dec 2025 stood at $52.1 million (up 8.18% YoY), and the FY2025 full-year result was $52.1 million, up 8.18% from the prior year.
• Finished Goods for Q4 2025 stood at $52.1 million, down from $64.3 million in the prior quarter.
• The five-year high for Finished Goods was $70.3 million in Q4 2023, with the low at $17.5 million in Q2 2021.
• Historically, Finished Goods has averaged $51.5 million across 5 years, with a median of $52.3 million in 2023.
• Annual changes were most pronounced in 2022 — Finished Goods soared 257.16% — and 2025, when it tumbled 32.47%.
• Adma Biologics' Finished Goods stood at $29.0 million in 2021, then soared by 101.6% to $58.5 million in 2022, then rose by 20.22% to $70.3 million in 2023, then sank by 31.54% to $48.1 million in 2024, then gained by 8.18% to $52.1 million in 2025.
• The last three Finished Goods figures came in at $52.1 million (Q4 2025), $64.3 million (Q3 2025), and $47.9 million (Q2 2025), per Business Quant data.